				ATTY DOCKET NO. 13105		SERIAL NO. 09/692,077			
10	NE	DRMATION DISCLOSURE	CITATION sary)						
MAY 1 0 2007 3					FILING October 19, 2000		GROUP 1614		
U.S. PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS (	SUBCLASS OF ING DATE  TE APPROPRIATE	
M		5,648,482	07/15/97	Meyer		536	<i>2</i> 4.33		
		5,846,710	12/08/98	Bajaj		435	6		
	•	<del>5,865,092</del> 5,856,092 <sup>19</sup>	01/05/99	Dale et a	al.	435	6		
		5,888,819	03/30/99	Goelet et al.		435	5		
		5,981,174	11/09/99	Wolf et al.		435	6		
		6,004,744	12/21/99	Goelet et al.		435	S		
		6,013,431	01/11/00	Soderlui	nd et al.	435	S	15	
DAS		6,156,503	12/05/00	Drazen et al.		435	6		
			7						
		4						· .	
· .									
		-	FORE	IGN PATEN	IT DOCUMENTS		· · · · ·		
		DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS TRANSLATION YES NO		
		,		1 X					
			¥			·			
								-	
	<u> </u>								
	1	OTHER DOCUMEN	TS (Including	g Author,	Title, Date, Pertinent F	Pages, Etc.)			
igg)	Limbird, L. E. (1988) FASEB J 2, 2686-2695								
DAP	Eason, M. G. and Liggett, S. B. (1993) Mol.Pharmacol. 44, 70-75								
EXAMINER Date CONSIDERED 2/26/04									
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

Form PTO-A820 (also form PTO-1449) P09C/REV03

Patent and Trademark Office \* U.S. DEPARTMENT OF COMMERCE

PAGE

 $_{\rm of}$   $\leq$ 

		Docket Number (Optional)	Application Number		
OIP	E	13105	09/692,077		
INFOR	MATION DISCLOSURE CITATION	Applicant(s)			
MAY 1 0 2	nn ( several sheets if necessary)	Liggett et al.			
13	<u>u</u>	Filing Date October 19, 2000	Group Art Unit 1614		
PENCHANER	1 OFF		1014		
MINITIA PADEMA		, Title, Date, Pertinent Pages, Etc.)			
nnA	Handy, D. E., Flordellis, C. S., Bogdanova, N. N	., Bresnahan, M. R., and Gavras, H. (1	993) Hypertension 21, 861-865		
1200,	*	•			
1	Tavares, A., Handy, D. E., Bogdanova, N. N., Rosene, D. L., and Gavras, H. (1996) Hypertension 27, 449-455				
	Hein, L., Limbird, L. E., Eglen, R. M., and Kobi	ilka, B. K. (1999) Ann NY Acad Sci 88	1, 265-271		
4					
	Rohrer, D. K. and Kobilka, B. K. (1998) Physiol	Rev 78, 35-52			
1	, , , , , , , , , , , , , , , , , , , ,				
			·		
	Duffelo D D Ye Nickelo A J Chedel I M	/ / / / / / / / / / / / / / / / / / /			
	Ruffolo, R. R., Jr., Nichols, A. J., Stadel, J. M., a	and Hieble, J. P. (1993) Annu Rev Phai	rmacol Toxicol 32, 243-279		
` [					
	Sallinen, J., Haapalinna, A., Viitamaa, T., Kobili	ka, B. K., and Scheinin, M. (1998) The	Journal of Neuroscience 18, 3035-3042		
4			_		
1	Sallinen, J., Haapalinna, A., Macdonald, E., Viit. and Scheinin, M. (1999) Mol Psychiatry 4, 443-4	amaa, T., Lahdesmaki, J., Rybnikova, 452	E., Pelto-Huikko, M., Kobilka, B. K.,		
	, , , , , ,	7			
	Altman, J. D., Trendelenburg, A. U., MacMillan, (1999) Mol.Pharmacol. 56, 154-161	L., Bernstein, D., Limbird, L., Starke	, K., Kobilka, B. K., and Hein, L.		
	(1999) Mor. Harmacor. 30, 134-101				
<b>,</b>					
	Hein, L., Altman, J. D., and Kobilka, B. K. (1999	) Nature 402, 181-184			
K	·				
			,		
	Link, R. E., Desal, K., Hein, L., Stevens, M. E., C	hruscinski, A., Bernstein, D., Barsh. G	. S., and Kobilka, B. K. (1996) Science		
k	273, 803-805	, , ,	, , , , , , , , , , , , , , , , , , , ,		
. 1			*		
	Makaritsis, K. P., Handy, D. E., Johns, C., Kobill	a B Gavras I and Cavras H (1906	1) Hypertension 33 14 17		
	1	, 2., 3., 1., and 3., 11. (1).	y Hypertension 33, 14-17		
11.			·		
	Liggett, S. B., Ostrowski, J., Chestnut, L. C., Kur	rose H. Davin and J. D. Conn. M. C.	- 1 X - G 14 - D - X - (1000)		
Maria	J.Biol.Chem. 267, 4740-4746	ose, n., Raymond, J. R., Caron, M. G.	, and Letkowitz, R. J. (1992)		
EXAMINER DATE CONSIDERED 2/20/04					
		- 1, 60			
*EXAMINER: Initial i	f citation considered, whether or not citation is in conform	nance with MPEP Section 609; Draw line to	hrough citation if not in conformance and		
not considered. Includ	e copy of this form with next communication to applicant.				

		Docket Number (Optional)	Application Number		
OIPER	MATION DISCLOSURE CITATION	Applicant(s)	09/692,077		
/	Use several sheets if necessary)	Liggett et al.			
MAY 1 0 2001	<b>1</b>	Filing Date Optobor 10, 2000	Group Art Unit		
AMINER A	\$	October 19, 2000	1614		
MADEM AN	OTHER DOCUMENTS (Including Autho				
100-0	Eason, M. G., Morcira, S. P., and Liggett, S. B	3. (1995) J.Biol.Chem. 270, 4681-4688			
1800)			×		
	Eason, M. G. and Liggett, S. B. (1992) J.Biol.C	( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )			
	Eason, W. G. and Liggett, S. B. (1992) J.Dioi.C	7 nem. 207, 25475-25479	4		
			•		
	Jewell-Motz, E. A. and Liggett, S. B. (1995) Bi	ochem 34, 11946-11953			
			<i>J</i>		
	Kurose, H. and Lefkowitz, R. J. (1994) J.Biol.C	Chem. 269, 10093-10099			
	- W		X		
	İ		`		
	Pitcher, J. A., Freedman, N. J., and Lefkowitz,	z, R. J. (1998) Annu Rev Biochem 67, 692			
			* <b>*</b>		
	·		* .		
	Heinonen, P., Koulu, M., Pesonen, U., Karvone (1999) J Clin Endocrinol Metab 84, 2429-2433	en, M. K., Rissanen, A., Laakso, M., Val	ve, R., Uusitupa, M., and Scheinin, M.		
.,		•	· · ·		
	Baldwin, C. T., Schwartz, F., Baima, J., Burzst	vn M Destafano A I Covere I Ho	ndy D.F. Yoost O. Montol T		
	Manolis, A., Nicolaou, M., Bresnahan, M., Fari	rer, L., and Gavras, H. (1999) Am J Hyp	pertens 12, 853-857		
	Eason, M. G., Jacinto, M. T., and Liggett, S. B.	(1994) Mol.Pharmacol, 45, 696-702			
			<i>د</i> •		
	Jewell-Motz, E. A., Small, K. M., and Liggett, S	S. B. (2000) J.Biol.Chem			
	·	1. J. (2000) 3. Biol. Citem			
	Small, K. M., Forbes, S. L., Rahman, F. F., Brid	lges, K. M., and Liggett, S. B. (2000) J.	Biol.Chem. 275, 23059-23064		
			*		
-					
.\	Hausdorff, W. P., Bouvier, M., O'Dowd, B. F., 1 12657-12665	Irons, G. P., Caron, M. G., and Lefkowi	tz, R. J. (1989) J.Biol.Chem. 264,		
		·			
	Baron, B. M. and Siegel, B. W. (1990) Mol Pha	www.col 29 249 254			
nu 1	Baron, B. M. and Siegel, B. W. (1990) Mol Fhai	macor 30, 346-330			
115					
EXAMINER (	10	DATE CONSIDERED 2 / 2 /	1011		
Des	20 a Que / 20	2/2/2	0104		
+EVARATION V		/ / / / / / / / / / / / / / / / / / /			
	if citation considered, whether or not citation is in confo- ie copy of this form with next communication to applicat		hrough citation it not in conformance and		

			Docket Number (Optional)	Application Number	
9,4	rom,	ATION DISCLOSURE CITATION (A) Se several sheets if necessary)	13105 09/692,077 Applicant(s) Liggett et al.		
MAY 1	0 20m	So several sneeds if necessary)	Filing Date	Group Art Unit	
A SMANINER		<del>y)</del>	October 19, 2000	1614	
CAMINER WOODEN	NAK OF	OTHER DOCUMENTS (Including Author, Title	e, Date, Pertinent Pages, Etc.)		
(Jay)		Smith, P. K., Krohn, R. I., Hermanson, G. T., Malli Olson, B. J., and Klenk, D. C. (1985) Anal.Biochem.	a, A. K., Gartner, F. H., Provenzano 150, 76-85	, M. D., Pujimoto, E. K., Goeke, N. M	
		Onorato, J. J., Palczewski, K., Regan, J. W., Caron,	M. G., Lefkowitz, R. J., and Benov	ic, J. L. (1991) Biochem 30, 5118-5125	
		Jewell-Motz, E. A. and Liggett, S. B. (1996) J.Biol.C	Chem. 271, 18082-18087		
		MacMillan, L. B., Hein, L., Smith, M. S., Piascik, M	. T., and Limbird, L. E. (1996) Scien	nce 273, 801-805	
		Muses B B and College Mr. 2000 G. C.	- C		
		Munroe, P. B. and Caulfield, M. J. (2000) Curr Opi	A		
	11	Introduction to & -adreno	ceptors,"	$\mathcal{A}$	
	Rol	http://www.adrenoceptor.com/alphaintro.htm (We omson, E. & Hudson, A. "Adrenocepto	Pharmology" te visited March 19, 20	/ \_	
nn.A		http://www.tocris.com/adrenoceptor.htm. (Websi	te visited March 19, 20	001) mb	
(BKI)		Novem!	olr 1998 mg	Lvol, ppWA)	
	: .		*		
•					
EXAMINER	<u> </u>	aia Po	ATE CONSIDERED & 24	OY	
		ation considered, whether or not citation is in conformance	with MPEP Section 609; Draw line thr	ough citation if not in conformance and	

Page 1 of 1 **PTO FORM 4/92 FORM PTO - 1449 ATTY DOCKET: 10738-43** SERIAL NO. 09/692,077 LIST OF PATENTS AND APPLICANTS: Kersten M. Small et al FILING DATE: October 19, 2000 FOR APPLICANT'S INFORMATION FOR: ALPHA-2B-ADRENERGIC GROUP: 1634 DISCLOSURE STATEMENT RECEPTOR POLYMORPHISMS UNITED STATES LETTERS PATENT SUB Exr. DATE NAME CLASS DOCUMENT NUMBER (YOM) CLASS Init. 0 Jan. 21, 1997 Weinshank et al 7,21 DOS FOREIGN PATENT DOCUMENTS SUB DATE COUNTRY CLASS DOCUMENT NUMBER **CLASS** PCT April 26, 2001 WO 01 2 8 2 OTHER ART (INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.) HEINONEN P. et al: "Identification of a three-amino acid deletion in the alpha2B-adrenergic receptor that is associated with reduced basal metabolic rate in obese subjects." The Journal of Clinical Endocrinology and Metabolism, United States, July 1999, Vol. 84, No. 7, pages 2429-2433. BALDWIN C.T., et al: "Identification of a polymorphic glutamic acid stretch in the alpha2B-adrenergic receptor and lack of cb linkage with essential hypertension." American Journal of Hypertension: Journal of the American Society of Hypertension, United States, Sep. 1999, Vol. 12, No. 9, Pt. 1, pages 853-857. JEWELL-MOTZ, E.A. et al: "An acidic motif within the third intracellular loop of the alpha2C2 adrenergic receptor is required for agonist-promoted phosphorylation and desensitization." Biochemistry, United States 19 Sep. 1995, Vol. 34, No. 37, 19 September 1995, pages 11946-11953. COMINGS, D.E., et al: "Additive effect of three noradrenergic genes (ADRA2a, ADRA2C, DBH) on attention-deficit hyperactivity disorder and learning disabilities in Tourette syndrome subjects." Clinical Genetics, Denmark, March 1999, Vol. 55, No. 3, pages 160-172. MAKARITSIS K.P., et al: "Role of the alpha2B-adrenergic receptor in the development of salt-induced hypertension." Hypertension. United States, Jan. 1999, Vol. 33, No. 1, January 1999, pages 14-17. MICHEL M.C., et al: "Functional correlates of alpha(2A)-adrenoceptor gene polymorphism in the HANE study." Nephrology. cf Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association-European Renal Association. England, Nov. 1999, Vol. 14, No. 11, pages 2657-2663. FREEMAN K., et al: "Genetic polymorphism of the alpha 2-adrenergic receptor is associated with increased platelet cg aggregation, baroreceptor sensitivity, and salt excretion in normotensive humans." American Journal of Hypertension: Journal of the American Society of Hypertension. United States, Sep. 1995, Vol. 8, No. 9, pages 863-869. SMALL K.M., et al: "Polymorphic deletion of three intracellular acidic residues of the alpha 2B-adrenergic receptor decreases G protein-coupled receptor kinase-mediated phosphorylation and desensitization." The Journal of Biological Chemistry. United States, 16 Feb 2001, Vol. 276, No. 7, pages 4917-4922. SNAPIR A., et al: "An insertion/deletion polymorphism in the alpha2B-adrenergic receptor gene is a novel genetic risk factor for acute coronary events." Journal of the American College of Cardiology. United States, May 2001, Vol. 37, No. 6, pages ſVÐ 1516-1522.

**EXAMINER** 

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and no considered. Include copy of this form with next communication to applicant.

880785v1 10738-43

•



